Risk factors for breakthrough COVID‐19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis
Transplant Infectious Disease · 2023
DOI: 10.1111/tid.14125 ↗Kurz gefasst
Leserbrief in der Zeitschrift Transplant Infectious Disease, 2023. Verfasst von Dana L Abraham und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California San Diego Health, La Jolla, California, USA. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, Antibodies, Monoclonal, COVID-19, Transplant Recipients. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, University of California San Diego Health, La Jolla, California, USA.
- Center for Transplantation, University of California San Diego Health, La Jolla, California, USA.
- Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California San Diego Health, La Jolla, California, USA.
- Herbert Wertheim School of Public Health and Human Longevity, University of California San Diego, La Jolla, California, USA.
- Division of Infectious Diseases and Global Health, University of California San Diego Health, La Jolla, California, USA.
ORCID-Profile: Dana L Abraham, Alicia B Lichvar, Aleah L Brubaker, Saima Aslam, Benjamin Chen, Nancy Law
Zitieren
APA
Abraham, D. L., Lichvar, A. B., Brubaker, A. L., Haste, N., Chen, V., Abeles, S., Aslam, S., Yam, N., Horton, L., Chen, B., Binkin, N., & Law, N. (2023). Risk factors for breakthrough COVID‐19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis. Transplant Infectious Disease. https://doi.org/10.1111/tid.14125
Vancouver
Abraham DL, Lichvar AB, Brubaker AL, Haste N, Chen V, Abeles S, et al. Risk factors for breakthrough COVID‐19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis. Transplant Infectious Disease. 2023. doi:10.1111/tid.14125
BibTeX
@article{Abraham2023,
author = {Abraham, Dana L and Lichvar, Alicia B and Brubaker, Aleah L and Haste, Nina and Chen, Victor and Abeles, Shira and Aslam, Saima and Yam, Nancy and Horton, Lucy and Chen, Benjamin and Binkin, Nancy and Law, Nancy},
title = {Risk factors for breakthrough COVID‐19 infections in solid organ transplant recipients receiving tixagevimab/cilgavimab for pre‐exposure prophylaxis},
journal = {Transplant Infectious Disease},
year = {2023},
doi = {10.1111/tid.14125}
}
EUVIMED